Last reviewed · How we verify
CHS-0214
CHS-0214 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.
CHS-0214 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells. Used for Solid tumors (specific indication under clinical development).
At a glance
| Generic name | CHS-0214 |
|---|---|
| Sponsor | Coherus Oncology, Inc. |
| Drug class | Bispecific T-cell engager (BiTE) |
| Target | CD3 and tumor-associated antigen (specific target not publicly disclosed) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a bispecific T-cell engager (BiTE), CHS-0214 bridges cytotoxic T lymphocytes to tumor cells by binding CD3 on T cells with one arm and a tumor antigen with the other arm, thereby activating and redirecting T cells to recognize and eliminate cancer cells. This mechanism bypasses the need for traditional T-cell receptor recognition and can enhance anti-tumor immunity in solid tumors.
Approved indications
- Solid tumors (specific indication under clinical development)
Common side effects
- Cytokine release syndrome
- Immune-related adverse events
- Infusion reactions
Key clinical trials
- Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) (PHASE3)
- Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) (PHASE3)
- A Long Term Safety Extension Study (CHS-0214-05) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |